The Role of Prebiotics and Probiotics in Gastrointestinal Disease

Gastroenterology Clinics of North America

Volumn 47, Issue 1, 2018, Pages 179-191

  Floch, Martin H ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Dietary fiber; FMT; Prebiotics; Probiotics; Symbiotics

Indexed keywords

PREBIOTIC AGENT; PROBIOTIC AGENT;

ACUTE DIARRHEA; ANTIBIOTIC ASSOCIATED DIARRHEA; BACTERIAL STRAIN; CLOSTRIDIUM DIFFICILE INFECTION; CROHN DISEASE; DIARRHEA; DIETARY FIBER; FECAL MICROBIOTA TRANSPLANTATION; GASTROINTESTINAL DISEASE; HOSPITAL ACQUIRED DIARRHEA; HUMAN; ILEITIS; INFECTIOUS DIARRHEA; IRRITABLE COLON; LIVER DISEASE; NONHUMAN; REVIEW; ULCERATIVE COLITIS; INFLAMMATORY BOWEL DISEASE; MICROBIOLOGY;

DIARRHEA; GASTROINTESTINAL DISEASES; HUMANS; INFLAMMATORY BOWEL DISEASES; IRRITABLE BOWEL SYNDROME; LIVER DISEASES; PREBIOTICS; PROBIOTICS;

EID: 85041352166     PISSN: 08898553     EISSN: 15581942     Source Type: Journal    
DOI: 10.1016/j.gtc.2017.09.011     Document Type: Review

References (105)

1. Turnbaugh, P.J., Ley, R.E., Hamady, M., et al. The human microbiome project. Nature 449 (2007), 804–810.
2. Floch, M.H., Ringel, Y., Walker, W.A., The microbiota in gastrointestinal pathophysiology: implications for human health, prebiotics, probiotics, and dysbiosis. 2017, Elsevier Inc, Cambridge (MA).
3. Floch, M.H., Madsen, K.K., Jenkins, D.J.A., et al. Recommendations for probiotic use. J Clin Gastroenterol 40 (2006), 275–278.
4. Floch, M.H., Walker, W.A., Guandalini, S., et al. Recommendations for probiotic use-2008. J Clin Gastroenterol 42 (2008), S104–S108.
5. Floch, M.H., Walker, W.A., Madsen, K., et al. Recommendations for probiotic use-2011 update. J Clin Gastroenterol 45 (2011), S168–S171.
6. Floch, M.H., Walker, W.A., Sanders, M.E., et al. Recommendations for probiotic use-2015 update: proceedings and consensus opinion. J Clin Gastroenterol 49 (2015), S69–S73.
7. Report of joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria, October 2001.
8. Fuller, R., Probiotics in man and animals. J Appl Bacteriol 66 (1989), 365–378.
9. Gibson, C.R., Roberfroid, M.B., Dietary modulation of the human colonic microflora: introducing the concept of prebiotics. J Nutr, 125, 1995, 401.
10. Trowell, H., Burkitt, D., Heaton, K., Dietary fibre, fibre-depleted foods and disease. 1985, Academic Press, London.
11. nd edition, 1992, CRC Press, Boca Raton (FL), 15–18.
12. Boyle, R.J., Robins-Browne, R.M., Tang, M.L.K., Probiotic use in clinical practice: what are the risks?. Am J Clin Nutr 83 (2006), 1256–1264.
13. nd edition, 2009, John Wiley & Sons, Inc, Hoboken (NJ), 75–95.
14. Peery, A.F., Crockett, S.D., Barritt, A.S., et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology 149:7 (2015), 1731–1741.e3.
15. Chang, J.Y., Locke, G.R. III, McNally, M.A., et al. Impact of functional gastrointestinal disorders on survival in the community. Am J Gastroenterol 105:4 (2010), 822–832.
16. Ford, A.C., Quigley, E.M.M., Lacy, B.E., et al. Efficacy of prebiotics, probiotics, and synbiotics in irritable bowel syndrome and chronic idiopathic constipation: systemic review and meta-analysis. Am J Gastroenterol 109 (2014), 1547–1561.
17. Patel, R., DuPont, H.L., New approaches for bacteriotherapy: prebiotics, new-generation probiotics, and synbiotics. Clin Infect Dis 60 (2015), S108–S121.
18. Mearin, F., Lacy, B.E., Chang, L., et al. Bowel disorders. Gastroenterology 150 (2016), 1393–1407.e5.
19. Kim, H.J., Vazquez Roque, M.I., Camilleri, M., et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 17 (2005), 687–696.
20. Enck P. A probiotic fermented milk may help manage mild gastrointestinal discomfort in healthy female adults. (Gut Microbiota Research & Practice Website). 2017. Available at: http://www.gutmicrobiotaforhealth.com/en/probiotic-fermented-milk-may-help-manage-mild-gastrointestinal-discomfort-healthy-female-adults/. Accessed March 18, 2017.
21. Agrawal, A., Houghton, L.A., Morris, J., et al. Clinical trial: the effects of a fermented milk production containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Aliment Pharmacol Ther 29 (2009), 104–114.
22. Guyonnet, D., Chassany, O., Ducrotte, P., et al. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Aliment Pharmacol Ther 26:3 (2007), 475–486.
23. Roberts, L.M., McCahon, D., Holder, R., et al. A randomised controlled trial of a probiotic ‘functional food’ in the management of irritable bowel syndrome. BMC Gastroenterol, 13, 2013, 45.
24. Whorwell, P.J., Altringer, L., Morel, J., et al. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. Am J Gastroenterol 101 (2006), 1581–1590.
25. Quigley, E.M.M., Irritable bowel syndrome. Floch, M.H., Kim, A.S., (eds.) Probiotics: a clinical guide, 1999, SLACK Inc, Thorofare (NJ), 273–282.
26. Zeng, J., Li, Y.Q., Zuo, X.L., et al. Clinical trial: effect of active lactic acid bacteria on mucosal barrier function in patients with diarrhea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 28 (2008), 994–1002.
27. Michail, S., Kenche, H., Gut microbiota is not modified by randomized, double-blind, placebo-controlled trial of VSL#3 in diarrhea-predominant irritable bowel syndrome. Probiotics Antimicrob Proteins 3 (2011), 1–7.
28. Kim, H.J., Camilleri, M., McKinzie, S., et al. A randomized controlled trial of a probiotic, VLS#3, on gut transit and symptoms in diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther 17 (2003), 895–904.
29. Ducrotte, P., Sawant, P., Jayanthi, V., Clinical trials: Lactobacillus plantarum 299v (DSM 9843) improves symptoms of irritable bowel syndrome. World J Gastroenterol 18 (2012), 4012–4018.
30. Kim, H.J., Vazquez Roque, M.I., Camilleri, M., et al. A randomized controlled trial of a probiotic combination VSL#3 and placebo in irritable bowel syndrome with bloating. Neurogastroenterol Motil 22 (2005), 387–394.
31. Kajander, K., Hatakka, K., Poussa, T., et al. A probiotic mixture alleviates symptoms in irritable bowel syndrome patients: a controlled 6-month intervention. Aliment Pharmacol Ther 22 (2005), 387–394.
32. Kalman, D.S., Schwartz, H.I., Alvarez, P., et al. A prospective, randomized, double-blind, placebo-controlled parallel-group dual site trial to evaluate the effects of a Bacillus coagulans-based product on functional intestinal gas symptoms. BMC Gastroenterol, 9, 2009, 85.
33. Tap, J., Derrien, M., Tomblom, H., et al. Identification of an intestinal microbiota signature associated with severity of irritable bowel syndrome. Gastroenterology 152 (2017), 111–123.
34. Rembacken, B.J., Snelling, A.M., Hawkey, P.M., et al. Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative colitis: a randomized trial. Lancet 354 (1999), 635–639.
35. Orel, R., Trop, T.K., Intestinal microbiota, probiotics, and prebiotics in inflammatory bowel disease. World J Gastroenterol 20 (2014), 11505–11524.
36. Biblioni, R., Fedorak, R.N., Tannock, G.W., et al. VSL#3 probiotic-mixture induces remission in patients with active ulcerative colitis. Am J Gastroenterol 100 (2005), 1539–1546.
37. Miele, E., Pascarell, F., Giannetti, E., et al. Effect of a probiotic preparation (VSL#3) on induction and maintenance of remission in children with ulcerative colitis. Am J Gastroenterol 104 (2009), 437–443.
38. Sood, A., Midha, V., Makharia, G.K., et al. The probiotic preparation VSL#3 induces remission in patients with mild to moderately active ulcerative colitis. Clin Gastroenterol Hepatol 7 (2009), 1202–1209.
39. Tursi, A., Brandimarte, G., Papa, A., et al. Treatment of relapsing mild to moderately active ulcerative colitis with probiotic VSL#3 as adjunctive to a standard pharmaceutical treatment: a double-blind, randomized, placebo-controlled study. Am J Gastroenterol 105 (2010), 2218–2227.
40. Chibbar, R., Alahmadi, A., Dieleman, L.A., Treatment of inflammatory bowel disease in ulcerative colitis. Floch, M.H., Ringel, Y., Walker, W.A., (eds.) The microbiota in gastrointestinal pathophysiology; implications for human health, prebiotics, probiotics, and dysbiosis, 2017, Elsevier Inc, Cambridge (MA), 343–354.
41. Machiels, K., Joossens, M., Sabino, J., et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prusnitzii defines dysbiosis in patients with ulcerative colitis. Gut 63 (2014), 1275–1283.
42. Rahimi, R., Nikfar, S., Rahimi, F., et al. A meta-analysis on the efficacy of probiotics for maintenance of remission and prevention of clinical and endoscopic relapse in Crohn's disease. Dig Dis Sci 53 (2008), 2524–2531.
43. van Loo, E.S., Dijkstra, G., Ploeg, R.J., et al. Prevention of postoperative recurrent of Crohn's disease. J Crohns Colitis 6 (2012), 637–646.
44. Sandborn, W.J., Pouchitis following ileal pouch-anal anastomosis: definition, pathogenesis and treatment. Gastroenterology 107 (1994), 1856–1860.
45. Fazio, V.W., Ziv, Y., Church, J.M., et al. Ileal pouch-anal anastomoses complications and function in 1005 patients. Ann Surg 222 (1995), 120–127.
46. Pardi, D.S., Sandborn, W.J., Management of pouchitis. Aliment Pharmacol Ther 23 (2006), 1087–1096.
47. Iwaya, A., Iiai, T., Okamoto, H., et al. Change in the bacterial flora of pouchitis. Hepatogastroenterology 53 (2006), 55–59.
48. Komanduri, S., Gillevet, P.M., Sikaroodi, M., et al. Dysbiosis in pouchitis, evidence of unique microfloral patterns in pouch inflammation. Clin Gastroenterol Hepatol 5 (2007), 353–360.
49. Gionchetti, P., Rizzello, F., Morselli, C., et al. High-dose probiotics for the treatment of active pouchitis. Dis Colon Rectum 50 (2007), 2075–2084.
50. Gionchetti, P., Rizzello, F., Venturi, A., et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis; a double-blind, placebo-controlled trial. Gastroenterology 119 (2000), 305–309.
51. Mimura, T., Rizzello, F., Helwig, U., et al. Once daily high dose probiotic therapy (VSL #3) for maintaining remission in recurrent refractory pouchitis. Gut 53 (2004), 108–114.
52. Shen, J., Zuo, Z.X., Mao, A.P., Effect of probiotics on inducing remission and maintaining therapy in ulcerative colitis, Crohn's disease and pouchitis: meta-analysis of randomized controlled trial. Inflamm Bowel Dis 20 (2014), 21–35.
53. Kuzela, L., Kascak, M., Vavrecka, A., Induction and maintenance of remission with nonpathogenic Escherichia coli in patients with pouchitis. Am J Gastroenterol 96 (2001), 3218–3219.
54. Tomasz, B., Zoran, S., Jaroslaw, W., et al. Long-term use of probiotics Lactobacillus and Bifidobacterium has a prophylactic effect on the occurrence and severity of pouchitis: a randomized prospective study. Biomed Res Int, 2014, 2014, 208064.
55. Guarino, A., Ashkenazi, S., Gendrel, D., et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition/European Society for Pediatric Infectious Diseases Evidence-based Guidelines for management of acute gastroenteritis in children in Europe: update. J Pediatr Gastroenterol Nutr 59 (2014), 132–152.
56. Johnston, B.C., Shamseer, L., de Costa, B.R., et al. Measurement issues in trials of pediatric acute-diarrheal diseases: a systemic review. Pediatrics 126 (2010), e222–e231.
57. Isolauri, E., Juntunen, M., Rautanen, T., et al. A human Lactobacillus strain (Lactobacillus casei sp strain GG) promotes recovery from acute diarrhea in children. Pediatrics 88 (1991), 90–97.
58. Guandalini, S., Probiotics for prevention and treatment of diarrhea. J Clin Gastroenterol 45 (2011), S149–S153.
59. Saavedra, J.M., Tschernia, A., Human studies with probiotics and prebiotics: clinical implications. Br J Nutr 87 (2002), S241–S246.
60. Saran, S., Gopalan, S., Krishna, T.P., Use of fermented foods to combat stunting and failure to thrive. Nutrition 18 (2002), 393–396.
61. Karas, J., Ashkenazi, S., Guarino, A., et al. A core outcome set for clinical trials in acute diarrhea. Arch Dis Child 100 (2015), 359–363.
62. Szajewska, H., Setty, M., Mrukowicz, J., et al. Probiotics in gastrointestinal diseases in children: hard and not-so-hard evidence of efficacy. J Pediatr Gastroenterol Nutr 42 (2006), 454–475.
63. Gutierrez-Castrellon, P., Lopez-Velazquez, G., Diaz-Garcia, L., et al. Diarrhea in preschool children and Lactobacillus reuteri: a randomized controlled trial. Pediatrics 133 (2014), e904–e909.
64. Thomas, D.W., Greer, F.R., American Academy of Pediatrics Committee on Nutrition, American Academy of pediatrics section on gastroenterology, hepatology, and nutrition. Probiotics and prebiotics in pediatrics. Pediatrics 126 (2010), 1217–1231.
65. Wittenberg, D.P., Management guidelines for acute infective diarrhea/gastroenteritis in infants. S Afr Med J 102 (2012), 104–107.
66. Chen, W.-Z., Ren, L.-H., Shi, R.-H., Enteric microbiota leads to new therapeutic strategies for ulcerative colitis. World J Gastroenterol 20 (2014), 15657–15663.
67. European Food Safety Authority Panel on Dietetic Products, Nutrition and Allergies. Scientific opinion on the substantiation of health claims related to non-characterised microorganisms pursuant to Article 13(1) of Regulation (EC) No 1924/20061. EFSA J, 7, 2009, 1247.
68. Wada, M., Nagata, S., Saito, M., et al. Effects of the enteral administration of Bifidobacterium breve on patients undergoing chemotherapy for pediatric malignancies. Support Care Cancer 18 (2010), 751–759.
69. Szajewska, H., Guarino, A., Hojsak, I., et al. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for probiotics and prebiotics. J Pediatr Gastroenterol Nutr 58 (2014), 531–539.
70. Goldenberg, J.Z., Ma, S.S., Saxton, J.D., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev, 5, 2013 CD006096.
71. Szajewska, H., Canani, R.B., Guarino, A., et al. Probiotics for the prevention of antibiotic-associated diarrhea in children. J Pediatr Gastroenterol Nutr 62 (2015), 495–506.
72. Pattani, R., Palda, V.A., Hwang, S.W., et al. Probiotics for the prevention of antibiotic-associated diarrhea and Clostridium difficile infection among hospitalized patients: systemic review and meta-analysis. Open Med 7 (2015), e56–e67.
73. Fine, S., Kelly, C.R., FMT in Clostridium difficile and other potential uses. Floch, M.H., Ringel, Y., Walker, W.A., (eds.) The microbiota in gastrointestinal pathophysiology: implications for human health, prebiotics, probiotics, and dysbiosis, 2017, Elsevier Inc, Cambridge (MA), 315–326.
74. Eiseman, B., Silen, W., Bascom, G.S., et al. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery 44 (1958), 854–859.
75. Schwan, A., Sjolin, S., Trottestam, U., et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of homologous faeces. Lancet, 2, 1983, 845.
76. Bartlett, J.G., Chang, T.W., Gurwith, M., et al. Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298 (1978), 531–534.
77. Surawicz, C.M., Brandt, L.J., Binion, D.G., et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol 108 (2013), 478–498 [quiz: 499].
78. Brandt, L.J., Aroniadis, O.C., Mellow, M., et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol 107 (2012), 1079–1087.
79. Rossen, N.G., Fuentes, S., van der Spek, M.J., et al. Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149 (2015), 110–118.e4.
80. Colman, R.J., Rubin, D.T., Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systemic review and meta-analysis. J Crohns Colitis 8 (2014), 1569–1581.
81. Hamilton, M.J., Weingarden, A.R., Sadowsky, M.J., et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol 107 (2012), 761–767.
82. Lee, C.H., Steiner, T., Petrof, E.O., et al. Frozen vs. fresh fecal microbiota transplantation and clinical resolution of diarrhea in patients with recurrent Clostridium difficile infection: a randomized clinical trial. JAMA 315 (2016), 142–149.
83. Youngster, I., Sauk, J., Pindar, C., et al. Fecal microbiota transplant for relapsing Clostridium difficile infection using a frozen inoculum from unrelated donors: a randomized, open-label, controlled pilot study. Clin Infect Dis 58 (2014), 1515–1522.
84. Bajaj, J., Hylemon, P., Ridlon, J., et al. Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation. Am J Physiol 303 (2012), G675–G685.
85. Liu, J., Wu, D., Ahmed, A., et al. Comparison of the gut microbe profiles and numbers between patients with liver cirrhosis and healthy individuals. Curr Microbiol 65 (2012), 7–13.
86. Garcia-Tsao, G., Albillos, A., Barden, G.E., et al. Bacterial translocation in acute and chronic portal hypertension. Hepatology 17 (1993), 1081–1085.
87. Chang, C.S., Chen, G.H., Lien, H.C., et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology 28 (1998), 1187–1190.
88. Shukla, S., Shukla, A., Mehboob, S., et al. Meta-analysis: the effects of gut flora modulation using prebiotics, probiotics and synbiotics on minimal hepatic encephalopathy. Aliment Pharmacol Ther 33 (2011), 662–671.
89. Bajaj, J., Saeian, K., Christensen, L., et al. Probiotic yogurt for the treatment of minimal hepatic encephalopathy. Am J Gastroenterol 103 (2008), 1707–1715.
90. Sharma, P., Sharma, B., Puri, V., et al. An open-label randomized controlled trial of lactulose and probiotics in the treatment of minimal hepatic encephalopathy. Eur J Gastroenterol Hepatol 20 (2007), 506–511.
91. Agrawal, A., Sharma, B.C., Sharma, P., et al. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 107 (2012), 1043–1050.
92. Malaguarnera, M., Gargante, M., Malaguarner, G., et al. Bifidobacterium combined with fructo-oligosaccharide versus lactulose in the treatment of patients with hepatic encephalopathy. Eur J Gastroenterol Hepatol 22 (2009), 199–206.
93. Lunia, M.K., Sharma, B.C., Sharma, P., et al. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 12 (2014), 1003–1008.
94. Eguchi, S., Takatsuki, M., Hidaka, M., et al. Perioperative synbiotic treatment to prevent infectious complications in patients after elective living donor liver transplantation: a prospective randomized study. Am J Surg 4 (2011), 498–502.
95. Sawas, T., Al Halabi, S., Hernaez, R., et al. Patients receiving prebiotics and probiotics before liver transplantation develop fewer infections than controls: a systemic review and meta-analysis. Clin Gastroenterol Hepatol 13 (2015), 1567–1574.
96. Spencer, M., Hamp, T., Reid, R., et al. Association between composition of the human gastroenterology microbiome and development of fatty liver with choline deficiency. Gastroenterology 140 (2011), 976–986.
97. Miloh, T., Probiotics in pediatric liver disease. J Clin Gastroenterol 49 (2015), S33–S36.
98. Aller, R., De Luis, D., Izaola, O., et al. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patient, a double blind randomized clinical trial. Eur Rev Med Pharmacol Sci 15 (2011), 1090–1095.
99. Malaguarnera, M., Vacante, M., Antic, T., et al. Bifidobacterium longum with fructo-oligosaccharides in patients with non-alcoholic steatohepatitis. Dig Dis Sci 57 (2012), 545–553.
100. Wong, V.W., Won, G.L., Chim, A.M., et al. Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study. Ann Hepatol 12 (2013), 256–262.
101. Vajro, P., Mandato, C., Licenziati, M.R., et al. Effects of Lactobacillus rhamnosus strain GG in pediatric obesity-related liver disease. J Pediatr Gastroenterol Nutr 52 (2011), 740–743.
102. Horvath, A., Leber, B., Schmerboeck, B., et al. Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Aliment Pharmacol Ther 44 (2016), 926–935.
103. Ptaszyńska, A.A., Borsuk, G., Zdybicka-Barabas, A., et al. Are commercial probiotics and prebiotics effective in the treatment and prevention of honeybee nosemosis C?. Parasitol Res 115 (2016), 397–406.
104. Lecerf, J.M., Depeint, F., Clerc, E., et al. Xylo-oligosaccharide (XOS) in combination with inulin modulates both the intestinal environment and immune status in healthy subjects, while XOS alone only shows prebiotic properties. Br J Nutr 108 (2012), 1847–1858.
105. Lin, S.H., Chou, L.M., Chien, Y.W., et al. Prebiotic effects of xylooligosaccharides on the improvement of microbiota balance in human subjects. Gastroenterol Res Pract, 2016, 2016, 5789232.